VUNO INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28,300 KRW | +1.43% |
|
+8.43% | -32.62% |
| 26/03 | Vuno Inc. announced that it has received KRW 10.4 billion in funding | CI |
| 21/03 | Vuno Inc. announced that it expects to receive KRW 10.4 billion in funding | CI |
| Sales 2024 * | 28.3B 20.57M 1.71B | Sales 2025 * | 36.85B 26.79M 2.23B | Capitalization | 388B 282M 23.51B |
|---|---|---|---|---|---|
| Net income 2024 * | -4B -2.91M -242M | Net income 2025 * | -2B -1.45M -121M | EV / Sales 2024 * | 13.5 x |
| Net cash position 2024 * | 5.4B 3.93M 327M | Net cash position 2025 * | 13.7B 9.96M 830M | EV / Sales 2025 * | 10.2 x |
| P/E ratio 2024 * |
-87.6
x | P/E ratio 2025 * |
-181
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.65% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.43% | ||
| 1 week | +8.43% | ||
| Current month | -10.58% | ||
| 1 month | -14.11% | ||
| 3 months | -9.29% | ||
| 6 months | +12.52% | ||
| Current year | -32.62% |
1 week
26 100.00
29 500.00
1 month
25 150.0034 700.00
Current year
25 150.0041 850.00
1 year
16 170.0069 500.00
3 years
5 000.0069 500.00
5 years
5 000.0069 500.00
10 years
5 000.0069 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kyu Hwan Jung
FOU | Founder | 43 | 10/14/10 |
Hyun-Jun Kim
FOU | Founder | 47 | 10/14/10 |
Ye-Ha Lee
FOU | Founder | 46 | 10/14/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
In-Soo Baek
BRD | Director/Board Member | 45 | - |
Sang-Jin Lee
DFI | Director of Finance/CFO | 44 | 01/20/01 |
Jun-Il Gil
BRD | Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 28,300 | +1.43% | 85,982 |
| 25/24/25 | 27,900 | -3.29% | 95,470 |
| 24/24/24 | 28,850 | +1.41% | 153,613 |
| 23/24/23 | 28,450 | +0.35% | 214,593 |
| 22/24/22 | 28,350 | +8.62% | 246,590 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Vuno Inc is a Korea-based company primarily engaged in the development of medical diagnostic, predictive technologies and solutions based on artificial intelligence (AI) technology.The Company develops and manufactures medical imaging products that assist with medical image-based diagnosis such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and funduscopy; pathology products that assist in the detection of digital scanners, microscopy-based cell quantification and tumor cells; biosignal products that assist and predict diagnosis based on time-series biosignal data such as vital signs and electrocardiogram; medical voice products that automatically create medical charts based on voice recognition. In addition, the Company sells an embolic material product, Nexpear. The Company sells its products in domestic and overseas markets such as Japan, Europe, and the United States.
Sector
IT Services & Consulting
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
28,300
KRW
Average target price
45,000
KRW
Spread / Average Target
+59.01%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.62% | 282M | |
| +19.35% | 3.95B | |
| +1.79% | 3.04B | |
| -30.07% | 1.69B | |
| -51.18% | 852M | |
| -29.51% | 575M | |
| -17.14% | 320M | |
| -13.72% | 202M | |
| +8.70% | 143M | |
| -3.23% | 127M |
- Stock Market
- Equities
- A338220 Stock
